The offering included institutional investors specialized in healthcare and life sciences from the United States of America and Europe. The Company intends to use the net proceeds from the capital inc...
Read moreThe study, named CLEPSIDRA, will be conducted in several Spanish hospitals . CLEPSIDRA is a single - arm, open - label study of Iadademstat in combination with the standard of care treatment p latinum...
Read moreOryzon Genomics, compañía biofarmacéutica de fase clínica centrada en la epigenética para el desarrollo de terapias en enfermedades con importantes necesidades médicas no resueltas , ha recibido...
Read moreLa aprobación ha sido concedida por la Agencia Española del Medicamento. El estudio se hará en pacientes de Leucemia Mieloide Aguda (LMA) no elegibles para quimioterapia intensiva. Es el pri...
Read moreLa aprobación ha sido concedida por la Agencia Española del Medicamento. El estudio se hará en pacientes de 3 enfermedades psiquiátricas y 2 enfermedades neurodegenerativas. Es el primer ...
Read moreOryzon is finishing an on going double - blind, placebo - controlled Phase 1 clinical trial in healthy volunteer s of its proprietary oral LSD1 - MAOB dual selective inhibitor ORY - 2001. The company ...
Read moreThe offering included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe. The majority of the funds were raised from international investors, rei...
Read moreORY - 1001 (RG6016), Oryzon’s first clinical asset, is a highly potent and selective Lysine Specific Demethylase - 1 (LSD1) inhibitor for the treatment of leukemia and other malignancies, currently ...
Read moreOryzon Genomics, compañía biofarmacéutica de fase clínica centrada en la epigenética para el desarrollo de terapias en enfermedades con importantes necesidades médicas no resueltas, ha anunci...
Read moreOryzon Genomics (ISIN Code: ES0167733015 , ORY ), a public clinical - stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced ...
Read moreCon esta operación, la farmacéutica Reig Jofre ha culminado la adquisición del 50% de Geadic Biotech , convirtiéndose en accionista único de la biotecnológica titular de GynEC ® -DX , el primer...
Read more